Jubilant Pharmova Limited · NSE:JUBLPHARMA
Jubilant Pharmova — Q3 FY2025 Earnings Presentation
72 slides from Jubilant Pharmova's earnings presentation, Jan 31, 2025
Slide 1: Cover letter to stock exchanges
January 31, 2025 BSE Limited, National Stock Exchange of India Limited, Floor 25, P. J. Towers Exchange Plaza, Dalal Street, Fort Bandra-Kurla Complex, Bandra (E), Mumbai - 400 001 Mumbai - 400051 Scrip Code: 530019 Symbol: JUBLPHARMA Sub: Press Release along with Earnings Presentation Ref: Regulati
Slide 2: Jubilant Pharmova – Q3 & 9M'FY25 Results
Jubilant Pharmova Limited 1A, Sector 16A, Noida – 201301, India Tel.: +91 120 4361000 PRESS RELEASE www.jubilantpharmova.com Noida, Jan 31, 2025 JUBILANT PHARMOVA – Q3 & 9M’FY25 RESULTS Started commercial distribution of PYLARIFY® from PET Radiopharmacies Successfully completed Media Fill on Line 3
Slide 3: 9M'FY25 Financial Highlights and Segmental Performance
9M’FY25 Financial Highlights In 9M’FY25, Revenue grew by 7% on YoY basis to Rs. 5,306 Cr. EBITDA grew by 24% on YoY basis to Rs. 873 Cr. due to improved performance in Radiopharma, CDMO Sterile Injectables, CRDMO and Generics. Normalised profit after tax increased by 106% to Rs. 277 Cr. Overall in Y
Slide 4: About Jubilant Pharmova Limited
Overall, the medium term outlook continues to be positive on the back of the increase in large pharma clients, CDMO revenues and the addition in new capabilities. The API business reported revenues of Rs. 142 Cr., growth of 3% YoY. Q3’FY25 EBITDA stands at Rs. 20 Cr. EBITDA margins improved by 620 b
Slide 5: Contacts and Disclaimer
For more information, please contact: For Investors Siddharth Rangnekar Pankaj Dhawan CDR India Phone: +91 120 436 1105 Phone: +91 97699 19966 E-mail: Pankaj.dhawan@jubl.com E-mail: siddharth@cdr-india.com For Media Ryan Marshall Sandipan Ghatak Madison Public Relations Phone: +91-120 436 1026 Phone
Slide 6: Earnings Presentation Q3'FY25
Earnings Presentation Q3’FY25
Slide 7: Disclaimer
Disclaimer Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, the progress and results of research and development, potential product characteristics and uses, product sales potential and target dates f
Slide 8: Jubilant Bhartia Group - Snapshot
Jubilant Bhartia Group - Snapshot Jubilant Bhartia Group founded by Shyam S. Bhartia and Hari S. Bhartia, leading industrialists from India Strong presence in diverse sectors like Pharmaceuticals, Life Science Ingredients, Contract Research & Development Services and Therapeutics, Performance Polyme
Slide 9: Company Snapshot
Company Snapshot A global pharmaceutical company with strong team of approx. 5,500 multicultural people & Total Income at Rs. 7,124 Cr. (TTM*) 1 2 3 4 5 6 Allergy CDMO PROPRIETARY Radiopharma CRDMO GENERICS Immunotherapy Sterile Injectables NEW DRUGS • • Serves regulated • • Leading Leading contract
Slide 10: Revenue Split – 9M'FY25
Revenue Split – 9M’FY25 BU wise Revenue Split 10% Radiopharma 15% Allergy Immunotherapy 47% CDMO - SI CRDMO 18% Generics 10% Specialty Pharma ( Radiopharma, Allergy Immunotherapy ), CDMO-SI and CRDMO contributes 90% of revenues. Majority of revenues are USD denominated. 5
Slide 11: Global Manufacturing & Research Footprint
Global Manufacturing & Research Footprint World class manufacturing facilities, 2 state of the art research centers & 46 radiopharmacies Kirkland, Montreal, Canada Kirkland, Montreal, Canada Spokane, Washington, USA Spokane, Washington, USA CDMO – SteriIe Injectables Radiopharmaceuticals CDMO – Ster
Slide 12: Jubilant Pharmova – Q3'FY25
Jubilant Pharmova – Q3’FY25 Started distributing PYLARIFY® from PET Radiopharmacies; Successfully completed Media Fill on Line 3; Roorkee ramping up exports to US 1 2 3 4 5 6 INNOVATE STRENGTHEN GROW BUILD STEER DISCOVER Allergy CDMO PROPRIETARY Sterile Injectables CRDMO GENERICS Radiopharma Immunot
Slide 13: Radiopharmaceuticals
1 Radiopharmaceuticals Growing role in treatment of life threatening diseases Single-photon Emission Positron Emission Radiopharmaceutical Computed Tomography Tomography Therapeutics (SPECT Imaging) (PET Imaging) (Tx) • Uses “low-energy” radio • Radiation is systemically or locally delivered • Uses
Slide 14: Radiopharmaceuticals
Radiopharmaceuticals US radiopharmaceutical market is expected to reach approx. USD 20 Bn. by 2030, growing at a CAGR of 20 %+ US Radiopharmaceutical Market (USD Bn.) Growth Drivers and Key Trends • Growth driven by superior imaging and therapeutics profiles, new emerging isotopes with low off targe
Slide 15: Radiopharmaceuticals
Radiopharmaceuticals Consolidated market with high entry barriers Stringent manufacturing & regulatory environment Adherence with extensive license framework. Stringent manufacturing set up required to handle isotopes Managing time sensitive Forward integration logistics with radiopharmacies Radioac
Slide 16: Radiopharmaceuticals
Radiopharmaceuticals We are one of largest manufacturer in the addressable market in the US with a wide radiopharmaceutical portfolio Organ Type Product Key Indication Dx Tc99m-DTPA Pulmonary Embolism SPECT Lung Key Differentiators Dx Tc99m-MAA Pulmonary Perfusion SPECT Localizing metastases Dx SPEC
Slide 17: Radiopharmaceuticals
Radiopharmaceuticals Market leadership in select products - MAA, DTPA and I-131 Draximage ® MAA Draximage ® DTPA HICON® Sodium Iodine I 131 Solution USP MAA is used in the perfusion DTPA is used to assess HICON® is a radioactive phase of a ventilation/perfusion pulmonary ventilation function in ther
Slide 18: Radiopharmaceuticals
Radiopharmaceuticals Innovation Leadership in Ruby - Fill ®, Gaining market share consistently Growing Cardiac PET Market in the US Ruby-Fill ® Rubidium 82 generator and Elusion System ~420 • The RUBY-FILL® Rubidium 82 Generator ~375 contains accelerator produced Strontium-82, ~335 ~300 which decays
Slide 19: Radiopharmaceuticals
Radiopharmaceuticals Ruby-Fill® and Robust product pipeline to fuel future business growth New Product led volume Ruby-Fill® PET & SPECT Development of therapeutic growth Growth potential Product Pipeline product - MIBG • Gain market share in the • Target to launch new • Completed patient dosing gro
Slide 20: Radiopharmaceuticals
Radiopharmaceuticals Driving revenue growth Particulars ( Rs. Cr.) Q3’FY24 Q2’FY25 Q3’FY25 Y-o-Y 9M'FY24 9M'FY25 Y-o-Y • Q3’FY25 revenue grew 10% YoY on back of growth in Ruby-Fill ® and new product, Sulphur Colloid Revenue 241 251 265 10% 696 778 12% • Q3’FY25 EBITDA flattish YoY due to change in E
Slide 21: Radiopharmacy
Radiopharmacy US Radiopharmacy market is expected to grow on the back of novel PET & Therapeutic products SPECT Radiopharmacy PET Radiopharmacy Growth Drivers and Key Trends • Radiopharmacy dispenses and distributes radiopharmaceutical products • Consolidated market in US with top 3 radiopharmacy ne
Slide 22: Radiopharmacy
Radiopharmacy Consolidated market with high barriers to entry Consolidated Market Barriers to Entry Stringent Regulations # of radio # of 1 pharmacies SPECT PET hospitals Each treatment site is required to obtain a license from pharmacies pharmacies served in in the US the US Nuclear Regulatory Comm
Slide 23: Radiopharmacy
Radiopharmacy 2nd largest radiopharmacy network in the US 46 nuclear USP<825> pharmacies JDR network is USP 825 including SPECT Portland WD compliant. and PET MT ND ME OR MN VT ID Saginaw NH 1,800 SD Minneapolis WI Detroit Wilkes NY Boston >100 WY MI Phila- RI radiopharmaceutical number of Barre PA
Slide 24: Radiopharmacy
Radiopharmacy Investing in PET radiopharmacy network throughout the US to drive growth & profitability PET Radiopharmacy • Plans to invest USD 50 Mn. to expand PET radiopharmacy network by adding Six (6) sites in strategic locations throughout US • Investment shall position the company in the growin
Slide 25: Radiopharmacy
Radiopharmacy Expand Radiopharmacy network, Ride on volume & new product led industry growth Radiopharmacy Network New Product led volume Enhance Operational Expansion growth Efficiencies • Expand PET radiopharmacy • Increase volume for new • Further strengthen performance network by adding six (6)
Slide 26: Radiopharmacy
Radiopharmacy Volume to drive revenue growth & operational efficiency to drive margin expansion Particulars ( Rs. Cr.) Q3’FY24 Q2’FY25 Q3’FY25 Y-o-Y 9M'FY24 9M'FY25 Y-o-Y • Q3’FY25 revenue grew 13% YoY on the back of increase in volume from new products, however revenues growth got impacted by Indus
Slide 27: Allergy Immunotherapy
2 Allergy Immunotherapy Global market poised to reach USD 3 Bn. by 2028, growing at a CAGR of ~ 7% Most Common Allergies in US (2023) Global Allergy Immunotherapy Market ( USD Bn. ) Others Insect 6.4% 3.0 6.4% Food 2.2 10.0% Pollen 2.7 40.0% 2.0 Pet 10.9% 0.2 0.3 Mold Drug 2023 2028 12.7% 13.6% Non-
Slide 28: Allergy Immunotherapy
Allergy Immunotherapy Jubilant is #2 player in the US Sub-Cutaneous Allergy Immunotherapy market with strong entry barriers Strong Entry Barriers Key Differentiators • Highly concentrated US market with well established • # 2 player in the US SCIT allergy market & Sole Supplier players of Venom immu
Slide 29: Allergy Immunotherapy
Allergy Immunotherapy Balanced Product Portfolio Venom Extracts Allergenic Extracts Skin Testing Devices • Allergenic extracts (over 200 • Multiple skin test system includes • Venom extracts includes products for ComforTen, Quintest and Quintip products) includes products for Honey Bee, White-Faced
Slide 30: Allergy Immunotherapy
Allergy Immunotherapy Moving ahead on three pronged growth strategy Enlarge US Venom Segment Grow revenues in US Penetrate outside US market Allergenic extracts • Create customer awareness on • Use Venom products to increase • Penetrate the Europe market on the the Bee sting allergy through customer
Slide 31: Allergy Immunotherapy
Allergy Immunotherapy Sustained growth momentum • Q3’FY25 revenues grew by 7% on YoY basis. Particulars ( Rs. Cr.) Q3’FY24 Q2’FY25 Q3’FY25 Y-o-Y 9M'FY24 9M'FY25 Y-o-Y • Q3’FY25 EBITDA margin decreased YoY due to Revenue 161 170 171 7% 491 509 4% weakness in exports and production challenges for spec
Slide 32: CDMO - Sterile Injectables
3 CDMO - Sterile Injectables Demand expected to outpace the supply by 2027 Global CDMO-SI Market Size (in USD Bn.) Growth Drivers & Key Trends 20 • Increase in demand: Increasing number of 17 drugs/injectable in development pipeline driven by 16 biologics (65%+ of current pipeline) and LOEs 14 13 •
Slide 33: CDMO - Sterile Injectables
CDMO - Sterile Injectables Structurally attractive market with key differentiators driving our growth Strong Entry Barriers Key Differentiators • Majority of commercial contracts are typically long • Deep and long-term relationships with our customers duration (typically 3 years or more with auto re
Slide 34: CDMO - Sterile Injectables
CDMO - Sterile Injectables Collaborative partner with unique capabilities & strong customer relationships Full Suite of • Can handle Vial size from 2ml to 100 ml with batch size up to 2,000 ltr. Services • Full suite of services including sterile fill and finish (Liquid & Freeze dried), Ophthalmic (
Slide 35: CDMO - Sterile Injectables
CDMO - Sterile Injectables Doubling of capacity with state of the art technology at Spokane on track; Incremental revenue potential of $160m - $180m Timeline FY’24 FY’25 FY’26 FY’27 FY’28 LINE 3 Installation Media Fill Tech Transfer Commercial Production LINE 4 Design Construction Installation Media
Slide 36: CDMO - Sterile Injectables
CDMO - Sterile Injectables Driving Revenue growth • Q3’FY25 revenue stable YoY. Montreal facility Particulars ( Rs. Cr.) Q3’FY24 Q2’FY25 Q3’FY25 Y-o-Y 9M'FY24 9M'FY25 Y-o-Y restarted operations in Q3’FY25 and operated for partial quarter. Revenue 303 302 306 1% 858 932 9% • Q3’FY25 EBITDA margins in
Slide 37: CRDMO: Drug Discovery Services, CDMO & API
4 CRDMO: Drug Discovery Services, CDMO & API Both Drug Discovery Services and API/Formulation Development markets are expected to grow at ~5-6% CAGR Drug Discovery Services Market Size (USD Bn.) Growth Drivers for Drug Discovery Market 10 • Large Pharma companies to de-risk their supply chain by add
Slide 38: CDMO API market
CDMO API market CDMO API Market is estimated to grow at a CAGR of ~ 6%+ CDMO API Market Size (USD Bn.) Growth Drivers for API Market ~ 130 + • Although API market is dominated by the small molecules, higher growth is experienced by HPAPIs and large molecule segments 18 ~ 95 + 16 • Cost competitivene
Slide 39: CRDMO: Drug Discovery Services & API
CRDMO : Drug Discovery Services & API We provide end to end CRDMO services for drug substance in small molecules CRDMO - Drug Discovery Services CDMO CRDMO - API Integrated Chemistry Research Contract Development & Advanced Intermediate Drug Discovery Centre Innovation Centre Manufacturing Centre &
Slide 40: Drug Discovery Services
Drug Discovery Services Three Pronged growth strategy Add large Add Drive pharma customers capabilities CDMO • Formed a strategic partnership • Add large pharma customer • Drive CDMO: Building with Pierre Fabre to add segment and continue to be a capabilities in areas like development capabilities t
Slide 41: API
API Maximize market penetration & Transform operations by increasing cost effectiveness & asset utilisation Dominant position in select therapies • Comprehensive portfolio comprising of APIs from various therapeutic area - Central Nervous System, Cardiovascular System, Anti-infective and Anti- diabe
Slide 42: CRDMO DDS and API results
CRDMO DDS: Increasing revenue share from large pharma clients CRDMO API: Focus on profitable products ; Taking initiatives to reduce operating costs Drug Discovery Services Drug Discovery Services • Q3’FY25 revenue increased 32% YoY due to Particulars ( Rs. Cr.) Q3’FY24 Q2’FY25 Q3’FY25 Y-o-Y 9M'FY24
Slide 43: Generics
5 Generics Global market to grow at a CAGR of 5 to 6% in the next 5 years Generics Market (USD Bn.) Overall Market • Overall market is growing on the back of increase in Chronic disease prevalence, loss of exclusivity for innovator products negated by pricing pressure in select markets ~ 532 Develop
Slide 44: Generics
Generics Continued profitable operations in 9M’FY25 Key Products & Facilities • Therapeutic areas - Cardiovascular System, Central Nervous System, Gastrointestinal and Multi Specialty • Global presence with serving more than 50 countries including US, Europe, Canada, Japan, Australia and RoW • Build
Slide 45: Generics
Generics Engineered turnaround by improving quality, optimizing cost & scaling Non US international business Continuous Continuous Scaled up Quality Improvement Cost Optimisation Non US International business Implemented a large scale quality Implemented cost optimization Scaled Non US international
Slide 46: Generics
Generics Growth Strategy for key markets Grow the profitable Build business in Focus on profitability in the Non-US International market Indian Market US Market • Focus on scaling 2 key markets • Build and Scale branded • Focus on profitable sustainable to triple digit revenue in INR Cr. generics bu
Slide 47: Generics
Generics Continued profitable operations in 9M’FY25 Particulars ( Rs. Cr.) Q3’FY24 Q2’FY25 Q3’FY25 Y-o-Y 9M'FY24 9M'FY25 Y-o-Y • Q3’FY25 revenue stable YoY • Q3’FY25 EBITDA sharply improved YoY due to Revenue 199 173 200 0% 573 528 (8%) overhead cost savings & profitable product mix. EBITDA (31) 21
Slide 48: Proprietary Novel Drugs
6 Proprietary Novel Drugs Clinical stage precision therapeutics Advancing potent molecules to address unmet medical needs in Oncology & Auto immune diseases Lead Pre - Clinical Program Mechanism Indications Phase I /II Milestones Optimization (IND) ET (Essential Phase I data suggests thrombocythemia
Slide 49: Proprietary Novel Drugs
Proprietary Novel Drugs Key Indications for JBI - 802 Disease Indications Rationale JBI - 802 Response Non-Small cell lung cancer • STK11 mutation is observed in10-15% NSCLC (85 % of lung One patient with NSCLC having STK11 mutations showed (NSCLC) cancer is NSCLC). significant response on JBI-802,
Slide 50: Proprietary Novel Drugs
Proprietary Novel Drugs Phase Two & Investigator led clinical trials status for JBI-802 Key Indications Trial Status Company Sponsored Phase 2 trial ; First patient dosing done ; Interim data by 2025 • ET is a rare blood cancer that causes the bone marrow to produce too many platelets leading to str
Slide 51: Proprietary Novel Drugs
Proprietary Novel Drugs Key Indications for JBI - 778; Disease Indications Rationale JBI – 778 Response Non-Small cell lung cancer • EGFR (epidermal growth factor receptor) mutations are • PRMT5 mechanism is relevant to EGFR inhibitor refractory (NSCLC) with or without brain observed in 10 - 50% of
Slide 52: Proprietary Novel Drugs
Proprietary Novel Drugs Continue to invest in a calibrated manner • Continue to invest in a calibrated manner in two Particulars ( Rs. Cr.) Q3’FY24 Q2’FY25 Q3’FY25 Y-o-Y 9M'FY24 9M'FY25 Y-o-Y lead programs Revenue 0 0 0 0 0 EBITDA (5) (3) (5) (13%) (23) (14) 37% 47
Slide 53: Consolidated Reported Financials – Q3'FY25 & 9M'FY25
Consolidated Reported Financials – Q3’FY25 & 9M’FY25 Total Income growth (YoY) along with EBITDA margin expansion & PAT growth (YoY) Particulars ( Rs. Cr. ) Q3’FY24 Q2’FY25 Q3’FY25 Y-o-Y 9M'FY24 9M'FY25 Y-o-Y • Q3’FY25 Revenue grew by 9% YoY on the back of growth in revenue across all segments Reven
Slide 54: Key Ratios
Key Ratios Net Debt / Ebitda continues to improve Particulars ( Rs. Cr. ) Mar 31, 2024 Dec 31, 2024 • Net Debt / Ebitda continues to improve Net Debt ( On constant currency, Net of DIC ) 2,457 1,654 • USD 125 million voluntary prepayment in YTD FY25, including USD 25 million in Net Debt / Equity 0.4
Slide 55: Sustainability
Sustainability Received KPMG ESG Excellence award for Mid / Small Cap category in the Pharma & Healthcare sector in FY25 Climate B Water B Supply Chain B Achieved 93 percentile Achieved 85 percentile 12,895 patients consulted through 37 % reduction in Specific Greenhouse 23% reduction in Specific Wa
Slide 56: Summary – Q3'FY25
Summary – Q3’FY25 Radio Pharmaceuticals : New products and Ruby-Fill® maintaining growth momentum 1 Radio Pharmacies : Industry wide Technetium shortage impacted business, Commercial distribution of PLYARIFY® started 2 Allergy Immunotherapy : Q3’FY25 revenue grew YoY; EBITDA margins have started to
Slide 57: Financial Results Table
Financial Results Table Total Income ( Rs. Cr. ) Q3’FY24 Q2’FY25 Q3’FY25 9M'FY24 9M'FY25 FY24 Revenue (A) 1,677 1,752 1,822 4,944 5,306 6,703 a. Radiopharma 752 820 841 2,184 2,493 3,001 Radiopharmaceuticals 241 251 265 696 778 952 Radiopharmacies 511 568 576 1,488 1,715 2,050 b. Allergy Immunothera
Slide 58: Annexure
Annexure
Slide 59: Executive Leadership Team
Executive Leadership Team Shyam S Bhartia Hari S Bhartia Priyavrat Bhartia Arjun S Bhartia Chairman Co-Chairman Managing Director Joint Managing Director Arvind Chokhany Shantanu Jha Dr. Tushar Gupta Group CFO, Group CHRO COO, CRDMO Head, Corporate Strategy 54 Whole-time Director
Slide 60: Executive Leadership Team
Executive Leadership Team Harsher Singh Kyle Ferguson Chris Preti CEO - Jubilant Radiopharma CEO – Allergy Business CEO - CDMO Giuliano Perfetti Dr. Jaidev Rajpal Dr. Syed Kazmi CEO - CRDMO, Biosys CEO - Jubilant Generics CEO - Jubilant Therapeutics 55
Slide 61: JPM Business Strategy
JPM Business Strategy To strengthen the unique position of each of the business unit to enhance shareholder value 1 2 3 4 5 6 INNOVATE STRENGTHEN GROW BUILD STEER DISCOVER Allergy CDMO PROPRIETARY Radiopharma Sterile Injectables CRDMO GENERICS Immunotherapy NEW DRUGS • Continue to grow • Grow revenu
Slide 62: Shareholding Pattern
Shareholding Pattern As on 31st Dec 2024 0.6% 24.8% Promoter and Promoter Group Domestic Institutions 50.7% Foreign Institutions Non - Institutions 17.0% Employee Benefit Trust 7.0% 57
Slide 63: Glossary
GLOSSARY Abbreviation Details Abbreviation Details CVS Cardiovascular System MEA Middle East Africa CNS Central Nervous System LATAM Latin America CDMO Contract Development Manufacturing Organization LOE Loss of exclusivity CRDMO Contract Research & Development Manufacturing Organization FDA (US) U.
Slide 64: For More Information
For More Information For Investors: Pankaj Dhawan Siddharth Rangnekar Jubilant Pharmova Limited CDR India Ph: +91 120 436 1105 Ph: +91 +91 9769919966 E-mail: Pankaj.dhawan@jubl.com E-mail: siddharth@cdr-india.com For Media: Ryan Marshall Sandipan Ghatak Madison Public Relations Phone: +91-120 436 10
Slide 65: Q3'FY25 Q&A
Q3’FY25 Q&A Disclaimer Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, the progress and results of research and development, potential product characteristics and uses, product sales potential and ta
Slide 66: Radiopharmaceuticals Q&A
Radiopharmaceuticals Q1. Can you talk about growth in Ruby-Fill®? Answer: Ruby-fill® is a best in class Positron Emission Tomography (PET) radiopharmaceutical product used for Cardiac imaging through a non-invasive procedure of the myocardium, to evaluate regional myocardial perfusion in adult patie
Slide 67: Radiopharmaceuticals and Radiopharmacy Q&A
Answer: Q3’FY25 revenue grew 10% YoY to Rs. 265 Cr. on the back of growth in Ruby- Fill ® and new product Sulphur Colloid. Q3’FY25 EBITDA flat YoY at Rs. 125 Cr. due to change in product mix however overall 9M’FY25 EBITDA increased YoY by 5% to Rs. 370 Cr. Radiopharmacy Q6. What are the growth lever
Slide 68: Allergy Immunotherapy Q&A
2. Grow revenues in US Non-venom: We are leveraging our position in the venom segment to increase customer wallet share through portfolio selling. 3. Outside US Markets: Our strategy is to enter new markets in Europe, MEA and APAC, particularly for Venom products. Each market requires a different re
Slide 69: CDMO Sterile Injectables Q&A
Q11. What is the project status of the expansion project in Spokane? What is the maximum revenue potential for Line 3 & 4 and how much time it shall take to fill up the lines? Answer: The capacity expansion program in Spokane, Washington, USA is on track with respect to time and cost. We are pleased
Slide 70: CRDMO Q&A
Q14. We have seen an impressive revenue growth in Drug Discovery services? Can you talk about it the growth trajectory going forward? Answer: We are bullish on the mid and long term prospects of the CRO industry in India due to talent availability & gradual shifting of demand due to the preference f
Slide 71: API and Generics Q&A
due to cost optimisation and improvement in product mix. Industry wide pricing pressure still continues. Generics Q18. Can you explain Q3’FY25 generics results? Answer: After becoming profitable in Q2’FY25, the profitability improved in Q3’FY25. Overall 9M’FY25 EBITDA margin stands at 8%. The succes
Slide 72: Proprietary Novel Drugs Q&A
Answer: We continue to dose patients in global clinical trials involving both of our lead programs, Phase II trial for JBI-802 for Essential Thrombocythemia (ET) and select Myeloproliferative Neoplasms (MPN), and Phase I trial for JBI -778 for non-small cell lung cancer (NSCLC) and high grade Glioma